We are pleased to announce that the first patient has been successfully recruited into the ARTILLERY-CARDI (CarDI) trial at UMC Utrecht, the Netherlands.
This recruitment represents a significant milestone for the ARTILLERY project, marking the transition from development to real-world clinical evaluation. The CarDI trial is investigating how AI-powered risk prediction, based on routine planning CT scans, can enable earlier identification of long-term cardiovascular and other chronic disease risks in breast cancer survivors — without imposing any additional burden on patients.
As breast cancer survival rates continue to improve, the need for effective long-term survivorship care is growing. Many survivors face elevated risks of cardiovascular disease and other conditions that are often under-recognised. Through the ARTILLERY project, existing medical imaging data is transformed into actionable insights that can support better prevention, follow-up care, and quality of life.
Recruiting the first patient is an important step forward and a clear demonstration of successful collaboration between clinical centres, research institutions, technology partners, and patient advocates working together to advance patient-centred innovation in cancer survivorship.
We extend our sincere thanks to all partners and contributors who made this milestone possible,
